Highlights
- Arcus announced it will present at the Evercore and Citi investor conferences, scheduled for December 1 and 2, 2026.
- Third quarter 2026 net loss was $128 million, or $(1.00) per share, compared with $135 million a year earlier.
- Total revenues were $9 million for the third quarter of 2026, compared with $26 million a year earlier.
- In October 2026 the company sold 16.4 million shares at $17.50 per share, for gross proceeds of approximately $288 million.
Arcus Biosciences, Inc. (NYSE:RCUS) shares were trading at USD 15.86 on November 20, 2026, up 0.51%, with a relative Volume at time of 1.96. The clinical-stage biopharmaceutical company filed its report for the quarter ended September 30, 2026 on November 4, disclosed an October 2026 underwritten public offering, and announced participation in two investor conferences in December 2026.
Arcus is a Delaware corporation with principal executive offices in Hayward, California. It is a late clinical-stage biopharmaceutical company focused on developing molecules for patients with cancer and immunology diseases, using its internal small-molecule discovery capabilities. The company operates as one reportable and operating segment, has not generated Revenue from product sales, and has recognized revenue through collaboration and license arrangements with partners including Gilead and Taiho. Its fiscal year ends on December 31.
December Investor Conferences
Arcus announced that management will present at the Evercore and Citi conferences, scheduled for December 1 and 2, 2026.
Third Quarter 2026 Results
For the three months ended September 30, 2026, total revenues were $9 million, compared with $26 million a year earlier. License and development services revenue was $8 million, compared with $20 million, and other collaboration revenue was $1 million, compared with $6 million. Research and Development expenses were $117 million, compared with $141 million, and general and administrative expenses were $23 million, compared with $27 million. Loss from operations was $131 million, compared with $142 million. Net loss was $128 million, or $(1.00) per basic and diluted share, compared with $135 million, or $(1.27) per share.
For the nine months ended September 30, 2026, total revenues were $67 million, compared with $214 million. Research and development expenses were $352 million, compared with $402 million, and general and administrative expenses were $76 million, compared with $84 million. Loss from operations was $361 million, compared with $272 million. Net loss was $347 million, or $(2.74) per share, compared with $247 million, or $(2.39) per share.
Balance Sheet, Cash Flow and Offering
At September 30, 2026, cash and cash equivalents were $151 million, compared with $222 million at December 31, 2025, and marketable securities were $479 million, compared with $759 million. Total Assets were $818 million, compared with $1,139 million, and total long-term Debt was $102 million, compared with $99 million. Net cash used in Operating Activities for the nine months was $345 million, compared with $362 million.
In October 2026, Arcus issued 16.4 million shares of common stock in an underwritten public offering at a public offering price of $17.50 per share, for total gross proceeds of approximately $288 million, before deducting Underwriting discounts, commissions and offering expenses. The company said its cash, cash equivalents and marketable securities of $694 million at September 30, 2026, together with the proceeds from the October 2026 financing, are expected to fund planned operations into 2029. It also said it will need additional funding to support continuing operations and pursue its development strategy.
Casdatifan, Collaboration and Program Updates
In October 2026, Arcus announced new data from the ARC-20 platform study of casdatifan in clear cell renal cell carcinoma. With casdatifan plus zimberelimab in first-line treatment (n=30), the confirmed objective response rate was 50%, and landmark progression-free survival was 86% at six months and 69% at 12 months. With casdatifan plus cabozantinib in the second-line setting (n=43), median progression-free survival was 14.5 months and the confirmed objective response rate was 44%. With casdatifan monotherapy in late-line treatment (n=121), median overall survival was 35 months, median progression-free survival was 13 months and the confirmed objective response rate was 36%.
Gilead's option rights under the Gilead Collaboration Agreement ended on July 14, 2026, following Gilead's decision not to make the option continuation payment. In August 2026, Arcus announced the discontinuation of the Phase 3 PACIFIC-8 study of domvanalimab and subsequently executed a termination agreement with AstraZeneca.






Please wait processing your request...